Determination of related impurities in glimepiride tablets by the HPLC method

N. O. Savina, N. M. Ocherethyana, V. M. Britsun, N. V. Ostanina

Abstract


Glimepiride is one of the modern and effective drugs that counteract diabetes mellitus type 2. Like other drugs glimepiride must comply with quality standards set by relevant government departments.

Aim. To determine the content of related impurities in glimepiride tablets in order to assess the drug quality.

Materials and methods. The study was performed by the reversed-phase HPLC with a spectrophotometric detector in the isocratic mode, in the UV-region of the spectrum. To determine impurities the method of comparison with the solution having the known concentration of impurities and the active substance was used.

Results and discussion. It has been shown that the drug contains ≤ 0.18 % of identified and unidentified impurities.

Conclusions. The purity of the drug complies with the requirements of normative documents.


Keywords


glimepiride; tablets; quality control; diabetes mellitus type 2; HPLC; related impurities

Full Text:

PDF

References


Rasin, M. S. (2002). Vnutrishni khvoroby. Poltava: Formika, 345.

2. Derzhavna Farmakopeia Ukrainy (Second Ed., Vol. 1). (2015). Kharkiv: Ukrainskyi naukovyi farmakopeinyi tsentr yakosti likarskykh zasobiv, 1128.

Lukianchuk, E. (2015). Ezhenedelnik Apteka, 48, 1019. Available at: http://www.apteka.ua/article/350970

Basit, A., Riaz, M., Fawwad, A. (2012). Glimepiride: evidencebased facts, trends, and observations. Vascular Health and Risk Management, 8, 463–472. doi: 10.2147/vhrm.s33194

5. European Pharmacopoeia (Sixth Ed., Vol. 2). (2008). Nordlingen: Druckerei C. H. Beck, 1974.

6. Nakaz MOZ Ukrainy № 877 vid 19.08.2009. Pro zatverdzhennia Derzhavnoi tsilovoi prohramy «Tsukrovyi diabet». Available at : http://zakon4.rada.gov.ua/laws/show/8772009%D0%BF

7. Derzhavna naukovodoslidna laboratoriia z kontroliu yakosti likarskykh zasobiv. Available at: http://www.druglab.kiev.ua/

Kahn, S. E., Cooper, M. E., Prato, S. D. (2014). Pathophysiology and treatment of type 2 diabetes: Perspectives on the past, present, and future. The Lancet – 383 (9922), 1068–1083. doi: 10.1016/S01406736(13)621546

Olokoba, A. B., Obateru, O. A., Olokoba, L. B. (2012). Type 2 Diabetes Mellitus: A Review of Current Trends. Oman Medical Journal, 27 (4), 269–273. doi: 10.5001/omj.2012.68

Stefansson, E., Einarsdottir, A. B. (2015). Public health and prevention of blindness in diabetes. International Journal of Diabetes Mellitus, 3 (1), 13. doi:10.1016/j.ijdm.2011.01.011

Venkatasubramanian, R. T., Suresh, M. K., Sanjay, J. N., Sachin, B. G. (2006). WO 2006103690 A1. A novel process for preparation of substantially pure glimepiride; declared 18.05.2005; published 05.10.2006.

Zhu, H., Zhu, Sh., Zhang, X., Guo, Y., Shi, Y., Chen, Zh. (2013). Comparative efficacy of glimepiride and metformin in monotherapy of type 2 diabetes mellitus: metaanalysis of randomized controlled trials. Diabetology & Metabolic Syndrome, 5, 7074. doi: 10.1186/17585996570


GOST Style Citations


1.         Внутрішні хвороби / Ред. М. С. Расін. – Полтава : Форміка, 2002. – 345 с.

2.         Державна фармакопея України, Т. 1. – Х. : Український науковий фармакопейний центр якості лікарських засобів. – 2015. – 1128 с.

3.         Лукьянчук, Е. // Еженедельник Аптека. – 2015. – № 48. – C. 1019. Режим доступу : http://www.apteka.ua/article/350970

4.         Basit, A. Glimepiride : evidence–based facts, trends, and observations / A. Basit, M. Riaz, A. Fawwad // Vasc. Health Risk Manag.  – 2012. – Vol. 8. – P. 463–472. doi: 10.2147/vhrm.s33194

5.         European Pharmacopoeia, Sixth Ed., Vol. 2. – Nordlingen : Druckerei C. H. Beck, 2008. – 1974 p.

6.         Про затвердження Державної цільової програми «Цукровий діабет» : постанова Кабінету Міністрів України від 19 серпня 2009 р. № 877. – Режим доступу : http://zakon4.rada.gov.ua/laws/show/877–2009–%D0%BF

7.         Державна науково–дослідна лабораторія з контролю якості лікарських засобів. – Режим доступу : http://www.druglab.kiev.ua/

8.         Kahn, S. E. Pathophysiology and treatment of type 2 diabetes : Perspectives on the past, present, and future / S. E. Kahn, M. E. Cooper, S. D. Prato // The Lancet. – 2014. – Vol. 383, Issue 9922. – P. 1068–1083. doi: 10.1016/s0140–6736(13)62154–6

9.         Olokoba, A. B. Type 2 Diabetes Mellitus : A Review of Current Trends / A. B. Olokoba, O. A. Obateru, L. B. Olokoba // Oman Med. J. – 2012. – Vol. 27, Issue 4. – P. 269–273. doi: 10.5001/omj.2012.68

10.       Stefansson, E. Public health and prevention of blindness in diabetes / E. Stefansson, A. B. Einarsdottir // Int. J. Diabetes Mellitus. – 2015. – Vol. 3, Issue 1. – P.1–3. doi: 10.1016/j.ijdm.2011.01.011

11.       WO 2006103690 A1, PCT/IN2005/000164. A novel process for preparation of substantially pure glimepiride / Venkatasubramanian R. T., Suresh M. K., Sanjay J. N., Sachin B. G.; declared 18.05.2005 ; published 05.10.2006.

12.       Comparative efficacy of glimepiride and metformin in monotherapy of type 2 diabetes mellitus : meta–analysis of randomized controlled trials / H. Zhu, Sh. Zhu, X. Zhang et al // Diabetol. Metab. Syndr. – 2013. – Vol. 5, Issue 1. – P. 70–74. doi: 10.1186/1758–5996–5–70





DOI: https://doi.org/10.24959/nphj.17.2141

Abbreviated key title: Vìsn. farm.

ISSN 2415-8844 (Online), ISSN 1562-7241 (Print)